Cargando…
Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors
T2DM is a complex disease underlined by multiple pathogenic defects responsible for the development and progression of hyperglycaemia. Each of these factors can now be tackled in a more targeted manner thanks to glucose‐lowering drugs that have been made available in the past 2 to 3 decades. Recogni...
Autores principales: | Del Prato, Stefano, Chilton, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887932/ https://www.ncbi.nlm.nih.gov/pubmed/29171700 http://dx.doi.org/10.1111/dom.13169 |
Ejemplares similares
-
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential
por: Mikhail, Nasser
Publicado: (2008) -
Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI
por: Xue, Jujun, et al.
Publicado: (2020) -
Managing diabetic patients with moderate or severe renal impairment using DPP-4
inhibitors: focus on vildagliptin
por: Russo, Eleonora, et al.
Publicado: (2013) -
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
por: Saini, Kunika, et al.
Publicado: (2023) -
Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
por: Bailey, Clifford J., et al.
Publicado: (2019)